menu
    • menu
    [{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"K-679","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Kowa Company","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pemafibrate","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kowa Company","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Nicox SA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"HPAPI","year":"2025","type":"Licensing Agreement","leadProduct":"Bimatoprost","moa":"Prostanoid FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Kowa Company","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Solution","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Peretinoin","moa":"Retinoic acid receptor (RAR)","graph1":"Oncology","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Kowa Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase II","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Kowa Company","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"11","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kowa Company \/ Sanofi","highestDevelopmentStatusID":"11","companyTruncated":"Kowa Company \/ Sanofi"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tofogliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Kowa Company","highestDevelopmentStatusID":"11","companyTruncated":"Kowa Company \/ Kowa Company"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"K-237","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"K-755","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"K-924","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"},{"orgOrder":0,"company":"Kowa Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"K-924","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Kowa Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Company \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Company \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Kowa Company

    Menu

    Kowa Company

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan

                            Details : NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development in patients with open-angle glaucoma or ocular hypertension.

                            Product Name : NCX 470

                            Product Type : HPAPI

                            Upfront Cash : Undisclosed

                            August 05, 2025

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Nicox to Gain 3 Million in 2025 Milestones as NCX 470 Heads to Phase 3 in Japan

                            Details : Under the licensing agreement, Kowa holds the Japanese rights to research & development and commercialize NCX 470 (bimatoprost). It is being evaluated for the treatment of ocular hypertension.

                            Product Name : Undisclosed

                            Product Type : HPAPI

                            Upfront Cash : $3.2 million

                            May 27, 2025

                            Lead Product(s) : Bimatoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Recipient : Nicox SA

                            Deal Size : $32.8 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K-679

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            K-679 Unimicelle Drug Shows Efficacy in EGFR-Positive Solid Tumors

                            Details : K-679 is a novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 21, 2025

                            Lead Product(s) : K-679

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intoler...

                            Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2023

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tofogliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Recipient : Shinshu University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

                            Details : Tofogliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 22, 2022

                            Lead Product(s) : Tofogliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Recipient : Shinshu University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K-237

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Confirmatory Study of K-237

                            Details : K-237 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 27, 2021

                            Lead Product(s) : K-237

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

                            Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hyperlipidemias.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Long Term Study of K-877 Extended Release Tablet

                            Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 20, 2021

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Confirmatory Study of K-877 Extended Release Tablet

                            Details : K-877 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyslipidemias.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 19, 2021

                            Lead Product(s) : Pemafibrate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed

                            Kowa Company

                            Japan arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : K-924

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            K-924 Phase III Confirmatory Study

                            Details : K-924 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 28, 2020

                            Lead Product(s) : K-924

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth